ResearchMoz

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

GBI Research
Published Date » 2013-10-09
No. Of Pages » N/A
   
 GBI Research, a leading business intelligence provider, has released its latest research report “Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). ...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.8 Treatment Algorithm

3 Marketed Products
3.1 Product Profiles
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc
3.1.3 Singulair (montelukast) – Merck & Co
3.1.4 Xolair (omalizumab) – Novartis and Genentech
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance

4 Asthma Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial Metrics Analysis
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab – Teva Pharmaceutical ltd
4.4.2 Mepolizumab - GlaxoSmithKline
4.4.3 Lebrikizumab – Roche/Genentech
4.4.4 Veramyst - GlaxoSmithKline
4.4.5 Andolast – Rottapharm Madaus
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the Asthma Therapeutics Market
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Licensing Deals
6.2 Major Co-development Deals

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.2 Market Forecast to 2019
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.3.1 References for Pipeline Heat Map
7.3.2 References for Marketed Heat Map
7.4 Market Definitions
7.5 Abbreviations
7.6 Methodology
7.7 Coverage
7.8 Secondary Research
7.9 Therapeutic Landscape
7.10 Epidemiology-Based Forecasting
7.10.1 Analogous Forecasting Methodology
7.11 Market Size by Geography
7.11.1 Forecasting Model for Therapeutic Areas
7.12 Geographical Landscape
7.13 Pipeline Analysis
7.14 Competitive Landscape
7.14.1 Expert Panel Validation
7.15 Contact Us
7.16 Disclaimer

List of Tables


Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths = 12 Years of Age and Adults
Table 4: Management of Chronic Asthma
Table 5: Management of Acute Asthma
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013
Table 13: Asthma, Global, Market Forecast, 2012–2019
Table 14: Asthma, US, Market Forecast, 2012–2019
Table 15: Asthma, Canada, Market Forecast, 2012–2019
Table 16: Asthma, UK, Market Forecast, 2012–2019
Table 17: Asthma, France, Market Forecast, 2012–2019
Table 18: Asthma, Germany, Market Forecast, 2012–2019
Table 19: Asthma, Italy, Market Forecast, 2012–2019
Table 20: Asthma, Spain, Market Forecast, 2012–2019
Table 21: Asthma, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III, 2013
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase I, 2013
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase II, 2013
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase III, 2013
Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase I, 2013
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase II, 2013
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase III, 2013
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase I, 2013
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase II, 2013
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase III, 2013
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014–2019
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015–2019
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015–2019
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014–2019
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015–2019
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014–2019
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat Map, 2013
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012–2019
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012–2019
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012–2019
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012–2019
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012–2019
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012–2019
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Treatment, 2012–2019
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012–2019
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and Terminated
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule Type, 2006–2012
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006–2013
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006–2013
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and Molecule Type, 2006–2013
Figure 49: Forecasting Model for Therapeutic Areas

Upcoming Reports:

Hormone Replacement Therapy Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts, 2012 - 2018
By - Transparency Market Research
Hormone replacement therapy (HRT) is administration of hormones to those patients who are under a phase of declining natural hormones in their body. Hormone replacement therapy is mostly administered to women undergoing menopausal phase. The hormones which are administered to patients are mostly Estrogen also supplemented by progesterone and testosterone. The modes of administration are oral tablets, implants, patches, vaginal creams etc. The global hormone replacement therapy market is expected to rise to approximately USD 3.6 billion by 2018. Also it is forecast that...
Greece: market of curtains, interior blinds and valances
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the curtains, interior blinds and valances market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the curtains, interior blinds and valances market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same...
Outage Management System (OMS) - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
OMS is a tool for identifying and improving the efficiency of restoration and communication with customers. OMS integrates with systems such as Supervisory Control and Data Acquisition System (SCADA), Distribution Automation (DA) System, Automatic Meter Reading (AMR), Advanced Metering Infrastructure (AMI), Customer Information System (CIS), Interactive Voice Response System (IVR) and Geographic Information System (GIS) for outage management.  OMS helps in analyzing outage events, calculate restoration time, and providing reliable outage report. The outage management functions...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Cable-free Charging Device Launched by the UPV
Aug 21, 2014  
A wireless energy transfer technology device has been developed by the researchers at the Universitat Politecnica de Valencia (UPV). The striking feature of this device is that one can charge electronic devices like laptops and mobile phones without using cables.  This patented system of the UPV makes use of resonators which have photonic crystals in which one is set on the...
Public Sector Employees Now Less Confident of Their Post-Retirement Security
Aug 21, 2014  
A new analysis reveals that employees in the public sector in the United States are more anxious today about their post-retirement safety than they were just two years ago.   The analysis says that only 18% of all full-time public sector employees that were a part of the survey said that they were ‘very confident’ about their post-retirement income security. This is a 3%...
Novartis to Handover Experimental TB drug to TB Alliance
Aug 21, 2014  
Novartis has signed a deal with the Global TB Alliance to handover its experimental tuberculosis medicine for further development and deployment, for no monitory gains it seems.  The deal is a clear indication how scrutiny over the company’s portfolio has been increased since Joerg Reinhardt took position as company’s new chairman. The new chairman is seen focusing more on...
China Market Loses Pace Again
Aug 21, 2014  
The Chinese manufacturing industry showed a weakening growth in August, which could mean that the world’s second-largest economy may soon have to take precautionary measures. HSBC’s manufacturing index’s preliminary version, which was released on Thursday, showed the Chinese index to decline to 50.3 from its 51.7 in July. The scale is a regular 100-point index, with a...
Does Chewing Gum Lead to Academic Productivity?
Aug 20, 2014  
Could chewing gum actually lead to improved academic productivity? A study conducted recently has found that there may possibly be a link between the two, finally making some headway in a decade-old research. The study called ‘The Effects of Gum Chewing on Math Scores in Adolescents’ was led by Craig Johnston from Baylor College of Medicine in Houston, Texas, and was sponsored by...